Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with relapsing Multiple Sclerosis (RMS).

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Keywords

Multiple Sclerosis (MS) Relapsing multiple sclerosis Multiple Sclerosis Sclerosis elezanumab Elezanumab Dose 1 Elezanumab Dose 2

Eligibility

You can join if…

Open to people ages 18-65

  • Subject has diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24 months
  • Subject has cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with multiple sclerosis (MS)
  • Subject has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test

You CAN'T join if...

  • Subjects must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening

Locations

  • UC Irvine Health /ID# 205728
    Irvine California 92697 United States
  • The Research Ctr Southern CA /ID# 204269
    Carlsbad California 92011-4219 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03737851
Phase
Phase 2
Study Type
Interventional
Last Updated